Human sera were tested for antibodies against the Epstein-Barr virus (EBV) latent infection terminal proteins (TPs). Anti-TP IgG and IgA antibodies were detected by an indirect immunofluorescence assay of insect cells expressing a recombinant TP1. Out of 301 human sera of patients with EBV-related and EBVunrelated disorders, only sera from patients with nasopharyngeal carcinoma (NPC) (32/83; 38 %) showed anti-TP antibodies. Studies on serial sera from German and Hong Kong NPC patients revealed a decline of anti-TP antibodies during tumour therapy, and none of these antibodies were identified in patients with early tumour stages or in remission. Comparative studies of TP1-specific polyclonal rabbit antisera and human TPpositive sera showed clear differences in the TP epitopes recognized by each. Human antisera contained antibodies only to native epitopes in exons 2 to 7 of TP1 whereas rabbit antisera reacted only with epitopes located in the first exon and, additionally, exhibited EBV strain specificities.
Introduction
The human herpesvirus Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis (IM). It is also associated with different human malignancies of B cell origin, for example with Burkitt's lymphoma (BL) and with nasopharyngeal carcinoma (NPC), a tumour derived from poorly differentiated epithelial cells (De The, 1982) .
The association of EBV and NPC was first revealed by serological evidence (Old et al., 1966) and was later reinforced by the consistent detection of EBV DNA in NPC tumour material (Wolf et aI., 1973) . In most countries NPC is rare, with rates of less than one case per 100000 people per year. However, in several Chinese populations (southern provinces of China, Hong Kong, Taiwan, Singapore and Malaysia) the incidence is 15 to 30 per 100000 each year (Waterhouse et al., 1982) . In these populations NPC is the most common tumour among men and the second most common among women.
EBV transcription has been characterized mainly in lymphoid cell lines. In non-permissively infected lymphoid cells nine viral antigens have been identified. The 1"Present address: Institut fttr Veterin~rvirologie, Switzerland. proteins expressed include six nuclear antigens (EBNAs; Kieff & Liebowitz, 1990) , the latent membrane protein (LMP; Mann et al., 1985) and the membrane-associated terminal proteins (TP1 and TP2; Longnecker & Kieff, 1990; Rowe et al., 1990; Frech et at., 1990) . The transcripts of the TPs are highly spliced. They share eight exons and differ only in the amino-terminal first exon of TP1, which is absent from TP2 (Laux et al., 1988; Sample et al., 1989) . According to its amino acid sequence, TP1 is a mainly hydrophobic protein with a hydrophilic amino terminus and an Mr of about 53K. TP2 lacks the hydrophilic amino terminus and has an Mr of about 40K. Both proteins are predicted to be integral membrane proteins with 12 transmembrane domains.
EBV infection of NPC cells is predominantly latent (Raab-Traub et al., 1983; Fahraeus et al., 1988; Young et al., 1988) . Examination of NPC tissues for specific viral antigens revealed the latent infection protein EBNA1 in immunoblots of all specimens but the absence of the other EBNAs, and the LMP was detected in approximately 65% of the specimens. Transcription data have also shown the expression of TP1 and TP2 in NPC tissues (Smith & Griffin, 1991 ; U. Zimber-Strobl, unpublished) .
Although lyric cycle proteins are not expressed in NPC tumour cells (Young et al., 1988) , elevated IgG and IgA antibody titres against EBV viral capsid antigen (VCA) and early antigens (EA) are well documented as useful diagnostic markers for NPC (Old et al., 1966; Henle & Henle, 1976; Hadar et al., 1986) . It has not only been demonstrated that NPC patients have increased antibody titres to EBV EA and VCA, but that they also show fluctuations in these titres with disease progression and following therapy of the tumour (Henle et al., 1973 (Henle et al., , 1977 . Anti-EBV IgA antibodies may also play a role in the development of EBV-associated NPC (Sixbey & Yao, 1992) . Elevated antibody titres to latent infection proteins with diagnostic potential have so far only been described for EBNA1 (Foong et al., 1990) .
In a preliminary study we found anti-TP antibodies restricted to sera from NPC patients (Frech et al., 1990) , so far a unique discovery for a latent infection protein.
We have extended our first studies by examining a greater number of sera from NPC patients and control groups, including follow-up studies of individual NPC patients. The serological response of anti-TP antibodypositive patients was characterized and the significance of anti-TP antibodies is discussed.
Methods
Cell lines and virus. All cell lines, detailed below, were maintained in RPMI 1640 medium supplemented with 10 % fetal calf serum, 40 units of penicillin per ml, 50 gg of streptomycin per ml, 10 units of moronal per ml, and 10 lag of neomycin sulphate per ml.
BL41 and BJAB are EBV-negative BL cell lines (Klein et al., 1974; Lenoir et al., 1985) . BL18, BL72, Ly91, Jijoye and Raji are EBVpositive BL cell lines (Lenoir et al., 1985; Hinuma et al., 1967; Pulvertaft, 1965) . Ly 117 is a B cell line established by co-cultivation of primary B lymphocytes with EBV derived from an NPC biopsy (Lenoir et al., 1985) . M-ABA is a marmoset cell line established by cocultivation of marmoset lymphocytes with EBV derived from an NPC, and B95-8 is a marmoset cell line established by co-cultivation with EBV derived from a patient with IM (Crawford et al., 1979; Miller & Lipman, 1973) . M-ABA/CBL and B95-8/CBL are cell lines established by immortalization of human cord blood lymphocytes with either of the EBV strains.
The insect cell line SF 158 was derived from Spodopterafrugiperda (fall armyworm) and was maintained in TNM-FH medium supplemented in the same way as the RPMI 1640 medium. The insect cells were infected by wild-type or recombinant baculoviruses as previously described (Summers & Smith, 1987) .
Recombinant baculoviruses. The recombinant baculoviruses carrying the complete reading frame of TP1 derived from an M-ABA/CBL cDNA library have been previously described (Frech et al., 1990) . Recombinant baculoviruses expressing a B95-8 TP1 derived from a B95-8 TP1 cDNA (Laux et al., 1988) were constructed using exactly the same strategy as for baculoviruses expressing the M-ABA TP1. The nucleotide sequence of the first exon of M-ABA TP 1 was determined by sequencing plasmid DNA using the Sequenase kit (United States Biochemical Corp.).
Recombinant prokaryotic expression vectors.
A pATH1 vector carrying the reading frame of the first exon of TP1 derived from the M-ABA strain of EBV and a pATH10 vector carrying the reading frame of TP1 derived from the M-ABA/CBL cDNA have been described (Frech et al., 1990) . A pATH10 vector carrying the reading frame of a B95-8 TP 1 was constructed using the same strategy as for the M-ABA/CBL TP1.
The pATH constructs encode fusion proteins containing 37K of the amino terminus of the anthranilate synthetase (TrpE) of Escherichia coli and either 11K (first exon; TrpE-1. exon TP1) or 51K of TP1 (TrpE-TP1). The induction of the fusion proteins and the crude purification of the proteins by excision from Coomassie blue-stained SDS-polyacrylamide gels have been described elsewhere (Spindler et al., 1984; Frech et al., 1990) .
Rabbit and human sera. A rabbit antiserum directed against the recombinant M-ABA TP1 expressed in the baculovirus system has been described before (Frech et al., 1990) . A rabbit antiserum directed against the prokaryotically expressed B95-8 TP1 was obtained using the previously described strategy for immunization (Frech et al., 1990) . Human serum samples were taken fiom 15 healthy Caucasian donors from Homburg, Germany, known to be seronegative for anti-VCA IgG antibodies; 20 healthy Caucasian donors from Freiburg, Germany, known to be seropositive for anti-VCA IgG antibodies; 21 IM patients from Homburg, Germany; 19 patients from Tunisia with EBVassociated BL; six patients from Tunisia with EBV-unrelated BL; 62 patients with Hodgkin's disease from K61n, Germany; 75 patients with EBV-unrelated diseases but elevated antibody titres to EBV antigens from Freiburg, Germany, and Tunisia; 39 NPC patients from Germany; 31 NPC patients from Tunisia; and 13 stage 3 and 4 NPC patients from Hong Kong. All EBV-positive sera were tested for anti-VCA IgG and IgA and anti-EA IgG antibodies. From eight German and 13 Hong Kong NPC patients 28 and 39 sequential serum samples were taken, respectively.
Immunofluorescence assays for anti-TP antibodies. Human sera were screened for IgG antibodies to the TPs by indirect immunofluorescence using acetone-fixed slide preparations of SF 158 cells infected with the TPl-expressing recombinant baculoviruses. All sera were tested at dilutions of 1 : 20 and 1 : 40 and detected with fluorescein isothiocyanateconjugated goat anti-human IgG antibodies. As a control the sera were tested in parallel on wild-type baculovirus-infected SF 158 cells. NPC sera were additionally assayed by serial doubling dilutions starting at 1:8 for IgG and IgA antibodies. For the competition assays 2 gl of sera diluted 1:40 in PBS were preincubated with either 20 to 50 gg of denatured recombinant proteins excised from SDS--polyacrylamide gels or 5 x 106 cells sonicated in PBS.
Affinity purification of anti-TP antibodies. E. coli cells expressing the 51K TrpE-TPI fusion proteins were sonicated in H20 and coupled to a CNBr-activated Sepharose 4B column (Pharmacia). Rabbit and human sera were applied to the column and were eluted with 100 mMglycine pH 2"5 and 100 mM-triethylamine pH 11. The acid and basic eluates were pooled and pre-tested in the indirect immunofluorescence assay.
Immunoblots. Cells were washed in PBS and then disrupted by sonication in a sample buffer containing 6% SDS, 10% mercaptoethanol and 8 M-urea. The proteins were separated on polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes as previously described (Towbin et al., 1979) . The blots were incubated with affinity-purified anti-TP antibodies and stained using peroxidaseconjugated goat anti-rabbit antibodies and a chemiluminescence protein detection method (Amersham).
Immunoprecipitation. E. coli or B cells expressing TP1 were lysed at 4 °C for 15 min in 0.5 % NP40 lysis buffer containing 100 mM-Tris-HC1 pH 9.0, 100 mM-NaC1, 5 mM-KC1, 0.5 mM-MgC12, 1 mM-CaC12, 1 mM-PMSF and 10 gg/ml aprotinin. Insoluble material was removed by centrifugation at 4 °C for 15 min at 10000g. Cell lysates were precleared for 1 h with Protein A-Sepharose, mixed with antibodies immobilized on Protein A Sepharose beads (Simanis & Lane, 1985) and incubated overnight at 4 °C. The beads were washed three times in lysis buffer and once in TE buffer. The antigen-antibody complexes were dissociated by boiling in SDS-containing sample buffer. The precipitated proteins were electrophoresed in SDS-polyacrylamide gets and detected by immunoblotting with an anti-TP1 rabbit antiserum or a human serum.
Results

Anti-TP antibodies in sera from NPC patients
The humoral immune response to the TPs of EBV was studied by an indirect immunofluorescence assay on known to be typical for NPC. No additional data concerning the tumour stages and the conditions of the patients were available. The 13 Hong Kong NPC sera [54% (7/13) anti-TP positive] represent a well-characterized collection of sera from NPC stage 3 and 4 patients, all taken during active disease before radiotherapy of the tumour.
Anti-TP antibody titres of individual NPC patients
Serum samples from eight German NPC patients, taken from 1986 to 1989, were tested for anti-TP antibodies (Table 1) . For each patient at least two serum samples and accompanying clinical data concerning tumour development and therapy were available. NPC1 to 3 were patients with localized tumours and few lymph node metastases. All three were positive for anti-TP antibodies before radiotherapy and became negative during treatment of the tumour. Patient NPC4 had a very early tumour stage showing no lymph node metastases and no anti-TP antibodies even before radiotherapy. NPC5 and 6 were long-term survivors tested during remission of the disease. NPC7 was a patient who showed a localized relapse during the period of therapy accompanied by an increase in anti-TP antibodies. NPC8 was a patient with a rapidly metastasing tumour, the only patient with increasing anti-TP titres.
Additionally, we tested 13 sera of a collection of Hong Kong NPC patients (HK1 to 13) of stages 3 and 4 from 1980 (Table 2 ). All patients were treated with radiotherapy (HK1 additionally received chemotherapy) and sera were taken before therapy (BT) and 3 or 6 months after therapy (MAT). Nearly all patients possessing anti-TP antibodies demonstrated a decline in titre so that, in some, antibodies were even no longer detectable after therapy.
Characterization of the IgG anti-TP antibody response in NPC patients
The specificity of human IgG anti-TP antibodies was further characterized by comparing it to the anti-TP antibody specificity of polyclonal antisera raised in rabbits against recombinant TP1 proteins.
A comparison of two rabbit antisera raised against M-ABA and B95-8 TP1, respectively, showed strainspecific differences in reactivity in the immunoblot (Fig.  2) . The serum raised against the M-ABA protein recognized TP1 in the cell lines M-ABA, M-ABA/CBL, BL18, BL72 and Ly117, but not in B95-8 or B95-8/CBL cellular extracts. The B95-8-specific serum recognized TP1 in all cell lines tested except BL72. The different reactivities of both TPl-specific antisera and the differences in band intensities in the immunoblot indicate strain-specific differences in TP1 epitopes. Both sera failed to detect the 40K TP2 protein and therefore no specific band was detected in the TPl-negative cell line Raji.
None of the human NPC sera that showed anti-TP antibodies in the indirect immunofluorescence assay detected TP1 or TP2 in the immunoblot (data not shown). To elucidate this phenomenon, the anti-TP reaction of the rabbit and human sera in the immunofluorescence assay with TPl-expressing insect cells was competed against by preincubation with different recombinant TP1 fusion proteins. The recombinant proteins were either expressed in E. coli and contained 37K of the M-ABA cells were lysed and TP1 was precipitated from the lysates with afffinity-purified antibodies from a TPl-specific rabbit antiserum, a TP-positive human antiserum and, as a control, from an LMP-specific rabbit antiserum (lanes 1 to 3 respectively). The precipitated proteins were detected by immunoblotting with an anti-TP1 rabbit antiserum. The 53K TP1 band is indicated by an arrowhead. (b) 1 x 106 E. coli cells were lysed and the TrpE-TP1 fusion proteins were precipitated with affinity-purified antibodies derived from a TP-positive human serum (lanes 2 and 4). The precipitated proteins were detected by immunoblotting with anti-TP human (lanes 1 and 2) or rabbit (lanes 3 and 4) antibodies. E. coli cells expressing only TrpE were used as a control (lanes 1 and 3) . The position of the fusion protein in the Coomassie blue-stained gel is indicated. The immunoblot shows degradation and aggregation of the fusion protein. The apparent Mrs were calculated from comigrating standards.
anthranilate synthetase (TrpE) of E. coli or expressed in the baculovirus system and contained nine aminoterminal polyhedrin amino acids. Five human sera with anit-TP titres greater than 1 : 128 were tested. In contrast to the rabbit antisera, the reaction of all human antisera tested could not be prevented by the hydrophilic amino terminus of TP1 (TrpE-l.exon) and by denatured proteins. The reactions of the rabbit antisera could be completely inhibited by preincubation with the first exon of TP 1, indicating that the sera do not recognize epitopes in the other six coding exons. Sequencing of the first exon of M-ABA TP1 revealed five base pair changes when compared to the sequence of the B95-8 TP1 gene (Laux et al., 1988) . Four of the base pair substitutions resulted in amino acid changes (Table 3 ). The specificity of human anti-TP antibodies for native TP epitopes could also be demonstrated by a combined immunoprecipitation and immunoblot assay. Affinitypurified human anti-TP antibodies could precipitate TP1 from EBV-infected B cells (Fig. 3a) , but after denaturation in an SDS-polyacrylamide gel previously precipitated TrpE-TP1 fusion proteins were no longer recognized by the human antibodies (Fig. 3 b) .
Discussion
Elevated antibody titres to EBV antigens belonging to the VCA and EA complexes are used for early detection of NPC and, during the course of the disease, as markers for the prognosis of the tumour. Antibodies to latent infection proteins such as EBNA1, EBNA2 and LMP have also been found in sera from NPC patients, but they can also be present in sera from patients with other EBVrelated disorders (Foong et al., 1990; Seigneurin et al., 1987; Rowe et al., 1988) . In this paper we describe the first case of a latent infection protein with an antibody response restricted to NPC patients. Although about 200 sera from patients with EBV-related diseases, such as BL, Hodgkin's disease and IM, and sera from patients with EBV-unrelated diseases but elevated anti-VCA and anti-EA antibody titres were tested, not one of the sera showed anti-TP antibodies. The sera from patients with EBV-unrelated disorders were selected for anti-VCA and anti-EA titres comparable with those of NPC patients. It must be considered that NPC patients alone may show elevated anti-TP titres which are in the range of the sensitivity of the detection assay and that our immunofluorescence assay cannot detect low anti-TP antibody titres. However, since the anti-TP titres in NPC patients cover a wide range (1:8 to 1:2048), this is not very probable. It has recently been suggested that Hodgkin's disease is EBV-associated (Herbst et al., 1991 ; Pallesen et al., 1991) and it has been shown that, as in NPC cells, the LMP is expressed in the tumour. Despite this, we could not detect anti-TP antibodies in sera from Hodgkin's disease patients, even in sera shown to be positive for anti-LMP antibodies (H.-F. Chen, personal communication). Finding anti-TP antibodies in sera from NPC patients alone may reflect an exceptional expression of the TPs in malignant epithelial cells in vivo in humans.
In vitro, the expression of TP1 and TP2 has been demonstrated in B cells (Frech et al., 1990; Longnecker & Kieff, 1990; Rowe et al., 1990) and in epithelial cells (Smith & Griffin, 1991; U. Zimber-Strobl, unpublished) . The correlation between NPC diagnosis and anti-TP antibodies was only about 40 % in our screen. To explain this, we tested serial sera from the NPC patients for whom clinical data concerning tumour development, therapy and prognosis were available. We found that active disease is often accompanied by increased anti-TP antibody titres. Patients who responded well to radio-or chemotherapy of the tumour showed a decline or even a disappearance of the anti-TP antibodies. Patients with early tumour stages and recovering patients were negative for anti-TP antibodies. This is a finding which has also been described for the EBV EA protein DNase (Tan et al., 1982; Chen et al., 1985) . Because it is difficult to obtain clinical data in a region with a low incidence of NPC and where it is not routine to take sera to follow the tumour development, the data can only be preliminary. The German and Tunisian collections include NPC patients' sera taken regardless of the turnout stage or whether the patient was recovering or not. This might explain the finding of only 30 to 40 % TP-positive sera.
In addition, sera were tested from 13 NPC patients from Hong Kong classified as stage 3 and 4 tumour patients with samples taken before and after tumour therapy. The pre-selection for late stages of NPC shifted the proportion of TP-positive sera to 54 %. The number of sera was not sufficient to decide whether stage 4 patients possess a higher percentage of TP-positive sera than stage 3 patients. It could again be observed that anti-TP antibody titres decline during the treatment of the tumour, although no real correlation could be found between numbers of lymph node metastases and anti-TP antibody titres. Unfortunately, no data are available detailing survival times and tumour recurrence. An extended study is currently being undertaken in Hong Kong to test more NPC sera, including sera from longterm survivors and from patients who died from NPC. As the carcinoma is often difficult to diagnose, an NPCrestricted marker would be very helpful for its identification. Our data indicate, however, that anti-TP antibodies cannot be found in early stages of NPC. The antibodies might, nevertheless, be important markers to evaluate tumour therapy or screen for tumour recurrence, especially as anti-VCA and anti-EA antibodies do not demonstrate comparable fluctuations in titre.
A comparison of the reactivity of human anti-TP antibodies to the antibody reactivity of rabbit anti-TP1 antibodies revealed that human anti-TP antibodies recognize only epitopes on native proteins located in the six coding exons shared by TP1 and TP2. The recognition of epitopes on native proteins alone reduces routine serological tests to either immunofluorescence or ELISAs. It is not yet possible to determine whether the absence of antibodies to the hydrophilic amino terminus of TP1 is due to a failure to present sequences of the first exon properly to evoke a B cell response or whether only TP2 is abundantly expressed in NPC in vivo. There are contradictory results on transcriptional expression of the two TPs in NPC cells (Smith & Griffin, 1991 ; Brooks et al., 1992; Busson et al., 1992) .
In contrast to the human anti-TP antibodies, rabbit anti-TP1 antisera recognized only the first exon of TP1 and exhibited strain-specific variations in reactivity which depended on the antigen used to raise the antibody response. A sequence comparison of the first exons of M-ABA and B95-8 TP1 revealed four amino acid changes which might cause these differences in reactivity. The amino acid changes observed in the NPC-derived M-ABA protein are identical to those found for the nude mouse-passaged NPC tumours C15 and C17 (Busson et al., 1992) . When comparing TP1 expression in different cell lines in the immunoblot, it should always be considered that different viral strains might differ in their epitopes and might therefore escape detection.
The restriction of detection of anti-TP antibodies to sera from NPC patients raises the question of whether the TPs play a role in the development of the epithelial tumour, perhaps in cooperation with the second LMP, which has been shown to be expressed in 65 % of NPC tumours and for which there exist indications of an association with TP1 in B cells in vitro (Longnecker et al., 1991) .
